Horseshoe crabs are bled for limulus amebocyte lysate (LAL) used in pharmaceutical safety testing, raising welfare concerns and prompting development of synthetic alternatives.
Horseshoe crab welfare during biomedical bleeding involves capture, transport to facilities, restraint, venepuncture, and then return release. The extent of suffering during this process is debated — horseshoe crab nervous systems are relatively simple, but they demonstrate aversion responses and post-bleeding physiological stress is measurable. Sub-lethal effects include reduced mobility, impaired haemolymph function, and disrupted spawning behaviour in released females. The welfare and conservation case for transitioning to synthetic rFC alternatives is compelling: equivalent safety, no animal use, and elimination of population pressure on a declining species. The pharmaceutical industry has been slow to adopt rFC despite validation; regulatory bodies including USP and European Pharmacopoeia are progressively updating standards to accommodate it.